Form 4: Instil Bio Director Gwendolyn Binder Granted 6,500 Stock Options

Instil Bio, Inc. Director Gwendolyn Binder was granted 6,500 stock options with an exercise price of $26.75, vesting over 12 months.

Summary

• Gwendolyn Binder, a Director of Instil Bio, Inc. (TIL), was granted 6,500 stock options on May 28, 2025.
• The exercise price for these stock options is $26.75 per share.
• The options will vest in 12 substantially equal monthly installments, commencing on June 28, 2025.
• Vesting is contingent upon Ms. Binder's continuous service with the company.
• Any unvested portion of the option will fully vest on the date of the next annual stockholder meeting, subject to continuous service.
• Full vesting will also occur in the event of Ms. Binder's death, Disability, or a Change in Control, as defined in the company's 2021 Equity Incentive Plan.
• The expiration date for these options is May 27, 2035.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is generally a neutral to slightly positive event, as it aligns the director's interests with shareholders and serves as an incentive for long-term performance. It does not, however, provide direct insight into operational or financial performance.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders, incentivizing long-term company performance.
• The vesting schedule encourages the director's continued commitment and service to the company.

Risks

• The value of the stock options is dependent on the future market price of Instil Bio's common stock, which may fluctuate.
• Vesting is subject to the reporting person's continuous service, meaning the options could be forfeited if service ceases before full vesting.

Future Outlook

The stock option grant and its vesting schedule indicate an expectation of continued service from the director and a long-term incentive structure tied to the company's performance.

Management Comments

• The filing was signed by Sandeep Laumas, M.D., as Attorney-in-Fact for Gwendolyn Binder.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, specifically an equity grant to a director, which is a common practice in publicly traded companies to align management and board interests with shareholders. Such grants are standard compensation components in the biotechnology and pharmaceutical sectors, where long-term value creation is paramount.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of options to a director aims to align their interests with shareholders, potentially leading to better long-term performance and value creation.
• Employees: While not directly impacting all employees, such grants are part of the company's overall compensation strategy, which can influence employee morale and retention at senior levels.

Next Steps

• Ongoing monthly vesting of the 6,500 stock options commencing June 28, 2025.
• Potential full vesting at the next annual stockholder meeting if not fully vested by then.

Key Dates

Keywords

Instil Bio, TIL, Stock Option, Director, Equity Incentive Plan, Insider Transaction, Form 4, Executive Compensation